Coverage
-
October 09, 2026
Sarepta Therapeutics Inc. no longer has to face a lawsuit accusing it of infringing a University of Pennsylvania gene therapy patent licensed by clinical-stage biotechnology company Regenxbio Inc. after the parties told a Delaware federal judge they agreed to end the case.
3 other articles on this case.
View all »